Richardson Electronics (RELL) Q3 2026 earnings review
Record Backlog Masks Underlying Profitability Squeeze
Richardson Electronics achieved its seventh consecutive quarter of YoY revenue growth, with sales up 3.1% (6.0% excluding the divested Healthcare unit). The top-line story is anchored by a surging PMT segment and a total backlog that accelerated 11.4% sequentially to a three-year high of $151.2 million. However, earnings quality reveals a different reality. While GAAP Net Income improved YoY due to prior-year divestiture charges, core profitability is decelerating. Operating expenses jumped 11.7%, causing current Q3 net income ($0.9M) to fall sharply compared to last year's adjusted non-GAAP net income ($1.6M). Meanwhile, the GES and Canvys segments completely reversed their growth trajectories, posting negative sales and margin compression. The top-line stability is commendable, but the operating leverage breakdown is a clear concern.
🐂 Bull Case
Total backlog spiked to $151.2M, the highest level in three years. This provides immense forward-looking revenue visibility, particularly in the semiconductor and RF markets.
Power & Microwave Technologies (PMT) continues to aggressively expand, posting 9.7% YoY growth (14.5% excluding Healthcare), accompanied by gross margin expansion to 32.1%. Semiconductor wafer fab demand remains a powerful secular tailwind.
🐻 Bear Case
Management touted 'continued discipline around operating expenses,' but reality contradicts this: OpEx grew 11.7% YoY compared to just 3.1% revenue growth. This wiped out gross margin gains and compressed adjusted earnings.
The Green Energy Solutions and Canvys segments—formerly key growth engines—both posted YoY revenue declines (-5.4% and -13.5%, respectively) while simultaneously suffering margin compression. Management blamed 'project timing,' but the dual top-and-bottom-line hit is a red flag.
⚖️ Verdict: ⚪
Neutral. The massive backlog jump and strength in the PMT segment guarantee near-term revenue stability. However, failing to convert that growth into bottom-line operating leverage due to ballooning OpEx and lagging secondary segments prevents a bullish outlook.
Key Themes
PMT Segment and Semiconductor Fab Recovery Accelerating
The PMT segment is single-handedly pulling the company forward. Sales accelerated 9.7% YoY (14.5% adjusting for the Healthcare exit), fueled by robust demand in the semifab equipment market and EDG products. This volume shift also drove a 220 basis point expansion in PMT gross margin to 32.1%. As legacy inventory issues at key semiconductor customers resolve, this high-margin revenue stream is converting to direct bottom-line strength.
Backlog Inflection Points to Energy & Macro Demand
After hovering flat around the $134M-$135M range for four consecutive quarters, total backlog violently accelerated by 11.4% sequentially to reach $151.2M. Management explicitly linked this to sustained macro demand across energy transition applications and semiconductor equipment. This forward-looking indicator significantly de-risks the FY26/FY27 revenue pipeline.
Expense Discipline Narrative Contradicted by Data
CEO Edward Richardson explicitly stated that growth was supported by 'continued discipline around gross margin and operating expenses.' The data strongly contradicts the latter half of that claim. Operating expenses accelerated dramatically, rising 11.7% YoY to $16.2M. Management justified this with 'critical adds to staff' and higher travel expenses. Consequently, Adjusted Operating Income fell from $2.2M in 25Q3 to just $1.5M in 26Q3. You cannot claim expense discipline when SG&A growth outpaces revenue growth nearly 4-to-1.
GES and Canvys Segments Reversing Course
Any segment growing below the company average is a concern, but both GES and Canvys actively contracted this quarter. GES reversed to a 5.4% YoY decline, while Canvys plummeted 13.5%. Worse, both segments suffered concurrent gross margin decay (GES down 200 bps to 30.8%; Canvys down 100 bps to 32.2%). While management routinely cites 'project timing' as the culprit, deteriorating margins suggest unfavorable absorption and pricing pressures rather than just delayed shipments.
Cash Burn Driven by Supplier Exits
Cash and cash equivalents fell sequentially from $33.1M to $29.5M. The primary driver of this cash use was an inventory build (inventories rose to $107.6M), specifically 'associated with final buys from a critical supplier.' Prior call transcripts indicate a major legacy power grid tube supplier is exiting the business, forcing Richardson into defensive inventory hoarding. This ties up working capital and limits free cash flow generation in the near term.
Consistent Gross Margin Expansion
Consolidated gross margin has proven exceptionally stable, expanding from 31.0% to 31.9% YoY. This indicates that despite competitive pressures in lagging segments, the company's core engineered solutions and PMT product mix possess genuine pricing power and healthy manufacturing absorption.
Other KPIs
Decelerating. While GAAP EBITDA swung from -$2.1M to +$2.2M YoY, last year's figure included a massive $4.9M one-time charge from the Healthcare divestiture. Adjusting for that, 25Q3 Adjusted EBITDA was $2.8M. Thus, true operational EBITDA actually contracted by roughly 21% YoY, directly mirroring the operating expense bloat.
Stable compared to traditional corporate norms, resulting in a $0.3M income tax provision for the quarter. Last year's tax line was distorted by the Healthcare unit sale, which created a $1.0M benefit.
Guidance
Stable to Accelerating. Management did not provide hard quantitative guidance ranges for the upcoming quarter or full year. However, they cited the three-year high in backlog as the foundation for 'confidence in our future growth outlook.' We expect the Q4 narrative to heavily depend on converting the massive $151.2M backlog into recognized PMT revenue.
Stable. The Board maintained the dividend at $0.06 per common share ($0.054 for Class B), indicating confidence in the company's baseline cash generation despite the temporary working capital drain from inventory builds.
Key Questions
Reconciling the Expense Narrative
You highlighted 'continued discipline' around operating expenses in the press release, yet OpEx grew 11.7% on 3.1% revenue growth. Can you detail exactly which 'critical adds to staff' were made, and when do you expect these investments to generate corresponding revenue leverage?
GES and Canvys 'Project Timing'
Both GES and Canvys revenues declined YoY due to 'project timing.' Does the $15M sequential spike in total backlog contain the delayed orders from these segments, and should we expect a snapback in Q4?
Critical Supplier Final Buys
You noted cash was used for inventory final buys from a critical supplier. How much more cash do you anticipate tying up in defensive inventory as this supplier exits the market, and when will that inventory be drawn down?